VARIANT OF THE CHEK2GENE AS A PROGNOSTIC MARKER IN GLIOBLASTOMA MULTIFORME
Authors:
- Matthias SimonMSMatthias Simon
- Michael LudwigMLMichael Ludwig
- Rolf FimmersRFRolf Fimmers
- Ralph MahlbergRMRalph Mahlberg
- Angelika Müller-ErkwohAMAngelika Müller-Erkwoh
- Gertraud KösterGKGertraud Köster
- Johannes SchrammJSJohannes Schramm
- 1 November 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Neurosurgery
- Vol. 59 (5) , 1078-1085
Abstract
Germline mutations of the CHEK2 tumor suppressor gene have been found in families with the Li-Fraumeni syndrome (LFS). Patients with LFS experience a variety of cancers, including malignant astrocytomas. We investigated a potential role for a CHEK2 gene polymorphism in glioblastomas. A genetic polymorphism of the CHEK2 gene (CHEK2 SNP rs2017309 A/T) was genotyped in a series of glioblastoma patients (n = 213) and population controls (n = 192). Subsets of tumors were analyzed for loss of heterozygosity 22q(n = 66), loss of heterozygosity CHEK2 (n = 53), CHEK2 expression (n = 21), and CHEK2 coding sequence alterations (n = 18). CHEK2 SNP rs2017309 genotyping findings and traditional clinicopathological parameters were correlated with the patients' prognoses. No association between the CHEK2 SNP and glioblastoma formation was observed. No CHEK2 coding sequence aberrations or tumors completely lacking CHEK2 protein were identified. However, the presence of the CHEK2 rs2017309 A allele was significantly associated with an adverse prognosis (P = 0.034), particularly among patients undergoing postoperative chemotherapy and radiotherapy (n = 28, median survival 10.5 versus 15.5 mo, P = 0.008). We could confirm the patients' age, Karnofsky Performance Scale score, and postoperative radiotherapy and chemotherapy (all P < 0.0001, log-rank test) as decisive prognostic factors. Our data suggest that a CHEK2 gene polymorphism might correlate with the prognosis of glioblastoma patients. These findings may point to an as yet unrecognized role for the CHEK2 gene in glioblastomas.Keywords
This publication has 33 references indexed in Scilit:
- Akt Activation Suppresses Chk2-Mediated, Methylating Agent–Induced G2 Arrest and Protects from Temozolomide-Induced Mitotic Catastrophe and Cellular SenescenceCancer Research, 2005
- Epidemiology and etiology of gliomasActa Neuropathologica, 2005
- CHEK2 Is a Multiorgan Cancer Susceptibility GeneThe American Journal of Human Genetics, 2004
- Fine mapping of chromosome 22q tumor suppressor gene candidate regions in astrocytomaInternational Journal of Cancer, 2003
- Neuro-Oncology Working Group 01 Trial of Nimustine Plus Teniposide Versus Nimustine Plus Cytarabine Chemotherapy in Addition to Involved-Field Radiotherapy in the First-Line Treatment of Malignant GliomaJournal of Clinical Oncology, 2003
- Identification of a novel candidate gene in the iron-sulfur pathway implicated in ataxia-susceptibility: human gene encoding HscB, a J-type co-chaperoneJournal of Human Genetics, 2003
- A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast CancerThe American Journal of Human Genetics, 2002
- Long survival and therapeutic responses in patient histologically disparate high-grade gliomas demonstrating chromosome 1p lossJournal of Neurosurgery, 2000
- Primary and secondary glioblastomas: From concept to clinical diagnosisNeuro-Oncology, 1999
- Randomized Comparisons of Radiotherapy and Nitrosoureas for the Treatment of Malignant Glioma after SurgeryNew England Journal of Medicine, 1980